Stoxline.com

Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Tango Therapeutics, Inc. (TNGX)

7.41   -0.04 (-0.54%) 11-28 10:44
Open: 7.43 Pre. Close: 7.45
High: 7.65 Low: 7.41
Volume: 126,757 Market Cap: 653(M)

Technical analysis

as of: 2022-11-28 10:22:28 AM
Overall:       
Stoxline posted a SELL today, same as yesterday. Downward movement continues.
Target: Six months: 9.22     One year: 9.99
Support: Support1: 6.84    Support2: 5.69
Resistance: Resistance1: 7.9    Resistance2: 8.55
Pivot: 7.71
Moving Average: MA(5): 7.62     MA(20): 7.7
MA(100): 5.22     MA(250): 6.7
MACD: MACD(12,26): 0.3     Signal(9): 0.4
Stochastic oscillator: %K(14,3): 40.2     %D(3): 43.7
RSI: RSI(14): 57.5
52-week: High: 11.72  Low: 3.18
Average Vol(K): 3-Month: 218 (K)  10-Days: 159 (K)

Price, moving averages and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.
[ TNGX ] has closed above bottom band by 42.9%. Bollinger Bands are 48.6% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 6 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 7.75 - 7.81 7.81 - 7.85
Low: 7.25 - 7.32 7.32 - 7.38
Close: 7.35 - 7.45 7.45 - 7.52

Company Description

Tango Therapeutics, Inc., a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions. The company also develops Ubiquitin-specific protease 1, an inhibitor to treat patients with BRCA1 or BRCA2-mutant cancers; and Target 3 for STK11-mutant cancers. Tango Therapeutics, Inc. has a strategic collaboration with Gilead Sciences, Inc. for the discovery, development, and commercialization of a pipeline of therapies for patients with cancer. The company was founded in 2017 and is based in Cambridge, Massachusetts.

Headline News

Fri, 18 Nov 2022
More than two Tango in PRMT5 space; Amgen, Mirati in play - BioWorld Online

Wed, 16 Nov 2022
Wedbush Increases Tango Therapeutics (NASDAQ:TNGX) Price Target to $21.00 - MarketBeat

Mon, 14 Nov 2022
Tango Therapeutics: Behind The Recent Momentum (NASDAQ:TNGX) - Seeking Alpha

Thu, 10 Nov 2022
Tango Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Highlights - Yahoo Finance

Mon, 07 Nov 2022
Tango Therapeutics to Participate in Upcoming Investor Conferences - Tango Therapeutics (NASDAQ:TNGX) - Benzinga

Tue, 18 Oct 2022
Is it Time to Dump Tango Therapeutics Inc (TNGX) Stock After it Has Risen 57.93% in a Week? - InvestorsObserver

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Neutral
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Underperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Outperform
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 88 (M)
Shares Float 43 (M)
% Held by Insiders 15.2 (%)
% Held by Institutions 78 (%)
Shares Short 1,250 (K)
Shares Short P.Month 1,060 (K)

Stock Financials

EPS -0.98
EPS Est Next Qtl 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 3.09
Profit Margin (%) 0
Operating Margin (%) -424.2
Return on Assets (ttm) -12.9
Return on Equity (ttm) -31.7
Qtrly Rev. Growth 2
Gross Profit (p.s.) -0.47
Sales Per Share 0.27
EBITDA (p.s.) -1.15
Qtrly Earnings Growth 0
Operating Cash Flow -98 (M)
Levered Free Cash Flow -44 (M)

Stock Valuations

PE Ratio -7.89
PEG Ratio 0
Price to Book value 2.46
Price to Sales 27.92
Price to Cash Flow -6.91

Stock Dividends

Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Your Ad Here
android_stock_chart
StockChart iOS
stoxline_lite
StoxlineLite iOS
stoxline_pro
StoxlineLite iOS
Option_Calculator
OptionCalc iOS
android_stock_chart
StockChart Android
stoxline_lite
StoxlineLite Android
stoxline_pro
StoxlinePro Android
Option_Calculator
OptionCalc Android
(c) 2006-2022 Stoxline.com | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Stoxline.com nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Stoxline.com web site, a user agrees not to redistribute the information found therein.